Biomarkers of renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 3, 2014, Pages 243-251

  Ngo, Tin C ^a   Wood, Christopher G ^a   Karam, Jose A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers; Diagnostic; Predictive; Prognostic; Renal cell carcinoma

Indexed keywords

AMINO ACID; BINDING PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBONATE DEHYDRATASE IX; FASCIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN LIKE GROWTH FACTOR II MRNA BINDING PROTEIN 3; KI 67 ANTIGEN; MICRORNA; NUCLEIC ACID; PEPTIDE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN B; SURVIVIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; TUMOR MARKER;

ADVANCED CANCER; AMINO ACID BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; COST EFFECTIVENESS ANALYSIS; FAMILIAL CANCER; GENOMICS; HIGH RISK PATIENT; HUMAN; IMMUNE SYSTEM; INFLAMMATION; KIDNEY CARCINOMA; KIDNEY TUBULE CELL; KIDNEY TUMOR; METABOLOMICS; METASTASIS; MOLECULAR PATHOLOGY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SYSTEMATIC REVIEW; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; PROGNOSIS;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897095116     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.07.011     Document Type: Review

References (106)

1. Cho E., Adami H.-O., Lindblad P. Epidemiology of renal cell cancer. Hematol Oncol Clin North Am 2011, 25:651-665.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
3. Moch H. An overview of renal cell cancer: pathology and genetics. Semin Cancer Biol 2013, 23:3-9.
4. Thoenes W., Störkel S., Rumpelt H.J. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986, 181:125-143.
5. Störkel S., Steart P.V., Drenckhahn D., Thoenes W. The human chromophobe cell renal carcinoma: it's probable relation to intercalated cells of the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol 1989, 56:237-245.
6. Verdorfer I, Culig Z, Hobisch A, Bartsch G, Hittmair A, Duba HC, et al. Characterisation of a collecting duct carcinoma by cytogenetic analysis and comparative genomic hybridisation. Int J Oncol 1998, 13:461-464.
7. Decastro G.J., McKiernan J.M. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am 2008, 35:581-592. vi.
8. Pavlovich C.P., Schmidt L.S. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 2004, 4:381-393.
9. Verine J., et al. Hereditary renal cancer syndromes: an update of a systematic review. Eur Urol 2010, 58:701-710.
10. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
11. Wang M.C., Valenzuela L.A., Murphy G.P., Chu T.M. Purification of a human prostate specific antigen. Invest Urol 1979, 17:159-163.
12. Stamey T.A., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317:909-916.
13. Guinan P.D., Ablin R.J., Dubin A., Nourkayhan S., Bush I.M. Carcinoembryonic antigen test in renal cell carcinoma. Urology 1975, 5:185-187.
14. Cairns P. Renal cell carcinoma. Cancer Biomark 2010, 9:461-473.
15. Pavlovich C.P., Schmidt L.S., Phillips J.L. The genetic basis of renal cell carcinoma. Urol Clin North Am 2003, 30:437-454. [vii].
16. Arjumand W., Sultana S. Role of VHL gene mutation in human renal cell carcinoma. Tumour Biol 2012, 33:9-16.
17. Eichelberg C., Junker K., Ljungberg B., Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009, 55:851-863.
18. Linehan W.M., Srinivasan R., Schmidt L.S. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010, 7:277-285.
19. Gerlinger M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
20. Honda K., et al. Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. Jpn J Clin Oncol 2013, 43:103-109.
21. Li L., et al. DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol 2012, 22:384-394.
22. Niers T.M.H., Richel D.J., Meijers J.C.M., Schlingemann R.O. Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One 2011, 6:e19873.
23. Ganti S., Weiss R.H. Urine metabolomics for kidney cancer detection and biomarker discovery. Urol Oncol 2011, 29:551-557.
24. Kaya K., et al. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma. Scand J Urol Nephrol 2005, 39:25-29.
25. Frank I., et al. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 2003, 170:2217-2220.
26. Okhunov Z., et al. Evaluation of perirenal fat as a predictor of cT 1a renal cortical neoplasm histopathology and surgical outcomes. J Endourol 2012, 26:911-916.
27. Ignee A., et al. The value of contrast enhanced ultrasound (CEUS) in the characterisation of patients with renal masses. Clin Hemorheol Microcirc 2010, 46:275-290.
28. Wykoff C.C., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000, 60:7075-7083.
29. Bui M.H.T., et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004, 171:2461-2466.
30. Stillebroer A.B., et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol 2013, 64:478-485.
31. Lawrentschuk N., Davis I.D., Bolton D.M., Scott A.M. Functional imaging of renal cell carcinoma. Nat Rev Urol 2010, 7:258-266.
32. Divgi C.R., et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol 2013, 31:187-194.
33. Baer C., Claus R., Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res 2013, 73:473-477.
34. Zhao A., Li G., Péoc'h M., Genin C., Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 2013, 94:115-120.
35. Redova M., et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012, 10:55.
36. Wulfken L.M., et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 2011, 6:e25787.
37. De Martino M., Klatte T., Haitel A., Marberger M. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer 2012, 118:82-90.
38. Mustafa A., et al. Serum amino acid levels as a biomarker for renal cell carcinoma. J Urol 2011, 186:1206-1212.
39. Kaneko N., et al. Potential tumor markers of renal cell carcinoma: α-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. Int J Urol 2013, 20:530-535.
40. Su Kim D., et al. Composite three-marker assay for early detection of kidney cancer. Cancer Epidemiol Biomarkers Prev 2013, 22:390-398.
41. Elson P.J., Witte R.S., Trump D.L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988, 48:7310-7313.
42. Raj G.V., et al. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol 2008, 179:2146-2151. [discussion 2151].
43. Hutterer G.C., et al. Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram. BJU Int 2008, 101:39-43.
44. Sun M., et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 2011, 60:644-661.
45. Yao M., et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002, 94:1569-1575.
46. Schraml P., et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002, 196:186-193.
47. Lidgren A., et al. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol 2006, 50:1272-1277.
48. Klatte T., et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007, 13:7388-7393.
49. Jacobsen J., et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004, 93:297-302.
50. Rioux-Leclercq N., et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007, 38:1489-1495.
51. Leibovich B.C., et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007, 25:4757-4764.
52. Papworth K., Sandlund J., Grankvist K., Ljungberg B., Rasmuson T. Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma. Anticancer Res 2010, 30:2953-2957.
53. Wu X., et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 2012, 7:e35661.
54. Gewurz H., Mold C., Siegel J., Fiedel B. C-reactive protein and the acute phase response. Adv Intern Med 1982, 27:345-372.
55. Michigan A., Johnson T.V., Master V.A. Preoperative C-reactive protein level adjusted for comorbidities and lifestyle factors predicts overall mortality in localized renal cell carcinoma. Mol Diagn Ther 2011, 15:229-234.
56. Cross B.W., et al. Preoperative erythrocyte sedimentation rate independently predicts overall survival in localized renal cell carcinoma following radical nephrectomy. Int J Surg Oncol 2012, 2012:524981.
57. De Martino M., et al. Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC). BJU Int 2013, 111:E348-E353.
58. Choi Y., et al. Erythrocyte sedimentation rate and anaemia are independent predictors of survival in patients with clear cell renal cell carcinoma. Br J Cancer 2013, 108:387-394.
59. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
60. Frankenberger B., Noessner E., Schendel D.J. Immune suppression in renal cell carcinoma. Semin Cancer Biol 2007, 17:330-343.
61. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012, 24:207-212.
62. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
63. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
64. Thompson R.H., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006, 66:3381-3385.
65. Tollefson M.K., et al. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer 2007, 110:783-790.
66. Verhoven B., et al. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on radiation therapy oncology group (RTOG) 94-08. Int J Radiat Oncol Biol Phys 2013, 86:317-323.
67. Honma N., et al. Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy. Breast Cancer 2013, 10.1007/s12282-013-0455-5.
68. Wenzel M., et al. Novel survivin-related members of the inhibitor of apoptosis (IAP) family. Cell Death Differ 2000, 7:682-683.
69. Mahotka C., et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 2002, 100:30-36.
70. Byun S.-S., Yeo W.G., Lee S.E., Lee E. Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. Urology 2007, 69:34-37.
71. Baytekin F., Tuna B., Mungan U., Aslan G., Yorukoglu K. Significance of P-glycoprotein, p53, and survivin expression in renal cell carcinoma. Urol Oncol 2011, 29:502-507.
72. Parker A.S., et al. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer 2006, 107:37-45.
73. Hashimoto Y., Skacel M., Adams J.C. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?. Int J Biochem Cell Biol 2005, 37:1787-1804.
74. Tsai W.-C., et al. Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters. World J Urol 2007, 25:73-80.
75. Zigeuner R., Droschl N., Tauber V., Rehak P., Langner C. Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique. Urology 2006, 68:518-522.
76. Jin J.-S., et al. Increasing expression of fascin in renal cell carcinoma associated with clinicopathological parameters of aggressiveness. Histol Histopathol 2006, 21:1287-1293.
77. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4:915-925.
78. Schmidt L., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68-73.
79. Giubellino A., Linehan W.M., Bottaro D.P. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 2009, 9:785-793.
80. Gibney G.T., et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 2013, 24:343-349.
81. Nielsen J., et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999, 19:1262-1270.
82. Yaniv K., Yisraeli J.K. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene 2002, 287:49-54.
83. Jiang Z., et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006, 7:556-564.
84. Hoffmann N.E., et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008, 112:1471-1479.
85. Parker A.S., et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009, 115:2092-2103.
86. Motzer R.J., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
87. Escudier B., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
88. Sternberg C.N., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
89. Motzer R.J., et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007, 25:3958-3964.
90. Amato R.J., Jac J., Giessinger S., Saxena S., Willis J.P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009, 115:2438-2446.
91. Cohen E.E.W., et al. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer 2011, 47:1484-1489.
92. Plimack E.R., Hudes G.R. Selecting targeted therapies for patients with renal cell carcinoma. J Natl Compr Canc Netw 2011, 9:997-1006. [quiz 1007].
93. Escudier B., et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl. 7):vii65-vii71.
94. Jain R.K., et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009, 6:327-338.
95. Huang D., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70:1063-1071.
96. Tran H.T., et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012, 13:827-837.
97. Zurita A.J., et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2012, 23:46-52.
98. Van Erp N.P., et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009, 27:4406-4412.
99. Garcia-Donas J., et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011, 12:1143-1150.
100. Van der Veldt A.A.M., et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008, 99:259-265.
101. Swanton C., et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med 2010, 2:53.
102. Rink M., et al. Tissue-based molecular markers for renal cell carcinoma. Minerva Urol Nefrol 2011, 63:293-308.
103. Choueiri T.K., et al. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol Oncol 2012, 10.1016/j.urolonc.2012.07.004.
104. Porta C., et al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 2013, 84:115-122.
105. Lambrechts D., et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012, 13:724-733.
106. Armstrong A.J., George D.J., Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 2012, 30:3402-3407.